| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 193,3 k € | +16.1% | 166,5 k € | -3.2% | 171,9 k € | -61.4% | 445,3 k € | +78.8% | 249,0 k € | +70.1% | 146,4 k € | -30.9% | 211,8 k € | +0.7% | 210,3 k € | -19.5% | 261,3 k € | +109.6% | 124,7 k € | -53.5% | 268,0 k € | +12.1% | 239,1 k € | +18.9% | 201,2 k € | +5.2% | 191,3 k € | +0.3% | 190,7 k € | -5.7% | 202,3 k € | +34.9% | 150,0 k € | +79.8% | 83,4 k € | +29.6% | 64,4 k € | |
| EBITDA | 179,6 k € | +23.5% | 145,4 k € | -1.7% | 147,9 k € | -65.1% | 424,1 k € | +83.7% | 230,9 k € | +80.4% | 128,0 k € | -33.9% | 193,5 k € | +0.6% | 192,3 k € | -22.3% | 247,4 k € | +121.4% | 111,8 k € | -56.8% | 258,9 k € | +10.3% | 234,6 k € | +18.5% | 198,0 k € | +5.3% | 188,0 k € | -0.1% | 188,2 k € | -5.8% | 199,9 k € | +35.4% | 147,6 k € | +83.0% | 80,7 k € | +30.1% | 62,0 k € | |
| Operating profit | 152,9 k € | +29.6% | 118,0 k € | -2.1% | 120,5 k € | -69.9% | 400,7 k € | +88.6% | 212,4 k € | +96.8% | 107,9 k € | -36.8% | 170,8 k € | +0.9% | 169,3 k € | -22.9% | 219,7 k € | +191.5% | 75,4 k € | -66.4% | 224,2 k € | +11.5% | 201,1 k € | +22.1% | 164,7 k € | +5.4% | 156,2 k € | -4.9% | 164,2 k € | -7.4% | 177,3 k € | +39.1% | 127,5 k € | +119.3% | 58,1 k € | +362.7% | 12,6 k € | |
| Profit/loss | 116,8 k € | +10.0% | 106,2 k € | +321.7% | 25,2 k € | -91.9% | 311,3 k € | +114.5% | 145,1 k € | -16.6% | 174,1 k € | +125.1% | 77,3 k € | -32.3% | 114,2 k € | +57.5% | 72,5 k € | +79.8% | 40,3 k € | -77.6% | 180,2 k € | +35.0% | 133,5 k € | -2.2% | 136,5 k € | +34.6% | 101,4 k € | -19.3% | 125,6 k € | -13.1% | 144,5 k € | +161.1% | 55,3 k € | +7.2% | 51,6 k € | +1585.4% | 3,1 k € | |
| Equity | 774,7 k € | -6.9% | 831,9 k € | +4.7% | 794,7 k € | -10.1% | 883,7 k € | +13.5% | 778,4 k € | -3.9% | 810,1 k € | -55.1% | 1,8 M € | +4.5% | 1,7 M € | +7.1% | 1,6 M € | +4.7% | 1,5 M € | +2.7% | 1,5 M € | +13.6% | 1,3 M € | +1.8% | 1,3 M € | +11.8% | 1,2 M € | +9.6% | 1,1 M € | +13.4% | 934,7 k € | +18.3% | 790,2 k € | +7.5% | 734,9 k € | +7.6% | 683,3 k € | |
| Total assets | 1,0 M € | -2.8% | 1,1 M € | -5.0% | 1,1 M € | -17.7% | 1,4 M € | +22.3% | 1,1 M € | -1.3% | 1,1 M € | -39.3% | 1,9 M € | +5.3% | 1,8 M € | +6.0% | 1,7 M € | +3.4% | 1,6 M € | +1.6% | 1,6 M € | +17.7% | 1,4 M € | +1.1% | 1,3 M € | +11.3% | 1,2 M € | +12.6% | 1,1 M € | +13.6% | 946,2 k € | +14.5% | 826,0 k € | +6.9% | 772,8 k € | +10.7% | 698,1 k € | |
| Cash | 71,6 k € | -14.1% | 83,4 k € | -32.0% | 122,5 k € | -56.3% | 280,7 k € | +33.5% | 210,3 k € | +67.8% | 125,3 k € | -64.4% | 352,4 k € | +37.3% | 256,8 k € | -13.9% | 298,3 k € | +42.1% | 209,9 k € | -46.6% | 393,3 k € | +10.4% | 356,4 k € | -18.9% | 439,4 k € | -6.1% | 467,7 k € | +1.4% | 461,1 k € | +55.3% | 296,8 k € | +1896.4% | 14,9 k € | -10.1% | 16,5 k € | -9.7% | 18,3 k € | |
| Debts | 270,1 k € | +10.9% | 243,7 k € | -27.7% | 337,1 k € | -31.4% | 491,5 k € | +72.3% | 285,3 k € | -13.4% | 329,6 k € | +350.8% | 73,1 k € | +33.4% | 54,8 k € | -21.0% | 69,4 k € | -20.7% | 87,5 k € | -14.2% | 102,0 k € | +162.2% | 38,9 k € | -19.6% | 48,4 k € | +0.1% | 48,4 k € | +245.2% | 14,0 k € | +25.7% | 11,2 k € | -68.8% | 35,7 k € | -5.8% | 37,9 k € | +167.6% | 14,2 k € | |
| Staff | — | — | — | — | — | — | — | — | — | 0,2 | 0,2 | 0,2 | — | — | — | — | — | — | — | |||||||||||||||||||
Private limited company · Amel · incorporated on 19/04/1994
Private limited company profitable and well capitalised. Cash position declining (-14.1%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
Dr. Huppertz-Marx is a Private limited company incorporated in 1994. Its main activity is: General medical practice activities. Its registered office is in Amel.
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette